DOCSLIB.ORG

Advanced Therapeutic Options for Management of the Type II Diabetic Patient in Primary Care

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Advanced Therapeutic Options for Management of the Type II Diabetic Patient in Primary Care 8/10/17 One Size does not fit all !!! Advanced Therapeutic Options for Management of the Type II Diabetic Patient in Primary Care Carole Mackavey DNP, MSN, APRN, RN FNP-C University of Texas Health Science Center@ Houston Texas Outcomes Diabetes Type II Prevalence • Recognize and implement the best • In 2012, 29.1 million Americans, or 9.3% of the population, had diabetes. therapeutic options for advanced Diabetes Management • 1.4 million Americans are diagnosed with diabetes every year. • Understand the mechanism of action • Prevalence in Seniors: The percentage of Americans age 65 and older remains and side effects for the most common high, at 25.9%, or 11.2 million seniors (diagnosed and undiagnosed). - See diabetic agents more at: • Examine several case scenarios and discuss a plan of care for the patient. • Undiagnosed: Of the 29.1 million, 21.0 million were diagnosed, and 8.1 million were undiagnosed • Examine and discuss the role of the patient in the management of diabetes • In 2012, 86 million Americans age 20 and older had prediabetes; this is up from 79 million in 2010. http://www.diabetes.org/diabetes-basics/statistics/?referrer=https://www.google.com/ Complications/Co-Morbid Conditions • Hypoglycemia older • Hypertension • Dyslipidemia • CVD Death • Heart Attack • Stroke • Blindness and Eye Problems: retinopathy • Kidney Disease • Amputations http://www.diabetes.org/diabetes- basics/statistics/?referrer=https://www.google.com/#sthash.iSimJp8y.dpuf 1 8/10/17 Diabetes by Race/Ethnicity Things to keep in mind • Diabetes is primarily a self managed disease • The rates of diagnosed diabetes by race/ethnic background are: • Treatment decisions should be timely, rely on evidence-based guidelines, and • 7.6% of non-Hispanic whites be made collaboratively with patients based on individual preferences, • 9.0% of Asian Americans prognoses, and comorbidities. • 12.8% of Hispanics • 13.2% of non-Hispanic blacks • The patient MUST be involved in the decisions made regarding the • 15.9% of American Indians/Alaskan Natives management of their diabetes http://www.diabetes.org/diabetes-basics/statistics/?referrer=https://www.google.com/ Alpha-Glucosidase Inhibitors So Lets Review Diabetes Medication • Inhibit enzyme at intestinal brush border How do they work? • Slow absorption of carbohydrates • Usually starts working after the first dose Alpha-Glucosidase Inhibitors Examples of alpha-glucosidase inhibitors include: • Acarbose (Precose) • Acarbose- Precose. • Miglitol (Glyset) • Miglitol - Glyset. • Average A1C reduction: 0.5% to 0.8% • Voglibose. • SE: Flatulence, diarrhea, abdominal bloating • Precautions: Avoid when creatinine clearance < 25 mL per minute per 1.73 m2 (0.42 mL per second per m2) • Most effective when given with a starchy, high-fiber diet • Reverse hypoglycemia with glucose, not sucrose Alpha-glucosidase inhibitor - Wikipedia https://en.wikipedia.org/wiki/Alpha-glucosidase_inhibitor 2 8/10/17 Alpha-Glucosidase Biguanides Inhibitors • Acarbose is able to reduce body weight, improve blood pressure, lower • Decrease hepatic glucose production; increase insulin sensitivity glucose levels, decrease in the incidence of newly diagnosed cardiovascular peripherally events and attenuate both fasting and post prandial hypertriglyceridemia. • Decrease intestinal absorption of carbohydrates • Usually works after 1-2 weeks • AGIs delays complex carbohydrate digestion. This mechanism of action leads to both wanted (lowering of glycemia) and unwanted (osmotic) effects. Undigested disaccharides which remain in the intestinal lumen may cause flatulence, diarrhea and abdominal pain. Kalra, S. (2014)Alpha glucosidase inhibitors Journal of the Pakistan Medical Association, retrieved http://jpma.org.pk/full_article_text.php?article_id=6311, Biguanides Metformin • Metformin- first line drug in treatment of type II diabetes • A1C reduction: 1.0% to 1.3% • The use of metformin as first-line therapy was supported by findings from a • SE: Nausea, diarrhea, abdominal bloating • Extended-release preparations have fewer gastrointestinal adverse large meta-analysis, with selection of second-line therapies based on effects patient-specific considerations • Precautions: Estimated GFR 30 to 44 mL per minute per 1.73 m2: review use of metformin • Metformin is effective and safe, is inexpensive, and may reduce risk of • Estimated GFR < 30 mL per minute per 1.73 m2: discontinue use • Discontinue during acute illness or procedure that could predispose cardiovascular events and death patient to lactic acidosis • American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37(suppl 1):S14-S80. • Powers AC, D'Alessio D. Chapter 43. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman's Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill; 2011 Metformin Metformin Liquid Metformin (Metformin Hydrochloride 500mg/5ml Oral Solution) can be • Metformin is associated with vitamin B12 deficiency, with a recent report given to improve tolerance in patients experiencing side effects at 500 mg from the Diabetes Prevention Program Outcomes Study (DPPOS) You can start of with ½ or 1 cc and gradually increase to 500 mg. suggesting that periodic testing of vitamin B12 levels should be considered in metformin-treated patients, especially in those with anemia or peripheral neuropathy. 3 8/10/17 Dipeptidyl-peptidase-4 inhibitors (DPP4) • Increase glucagon-like peptide-1 • Increase insulin secretion from β-cells and decrease glucagon secretion from α-cells in the pancreas • Medication starts to work after 1-2 weeks http://www.f6publishing.com/Pub/10.3748/v19/i15/WJG-19-2298-g001.jpg Dipeptidyl-peptidase-4 inhibitors List of FDA-approved DPP-4 inhibitors • Alogliptin (Nesina)* • Brand name Active ingredient(s) • Linagliptin (Tradjenta)* • Janumet XR sitagliptin and metformin extended release • Saxagliptin (Onglyza)* • Onglyza saxagliptin • Sitagliptin (Januvia)* • Kombiglyze XR saxagliptin and metformin extended release • AIC reduction 0.5% to 0.9% • Tradjenta linagliptin • SE: Headache, pancreatitis (rare) • 7 more rows • Precautions: Linagliptin does not require dosage adjustment in renal insufficiency • Saxagliptin dosage adjustment required when administered with concomitant CYP3A4 • FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors inhibitors • https://www.fda.gov/Drugs/DrugSafety/ucm459579.htm DPP4 Glucagon-like peptide-1 receptor agonists (GLP1) • Increase insulin secretion from β-cells and • DPP-4 inhibitors are taken orally with or without food and have once a day decrease glucagon secretion from α-cells in the dosing. pancreas • They are safer than sulfonylureas when comparing the rate of • Suppress hepatic glucose production; delay gastric hypoglycemic episodes. emptying •They do not affect weight. • Medication starts to work after 1st dose if short acting • In patients with impaired renal function, linagliptin is the only DPP-4 inhibitor and after 2 weeks if long acting like exenitide that does not require a dose adjustment. extended (Bydurion) & dulaglutide (Trulicity) • Rare hypoglycemia events http://ftp.rxeconsult.com/healthcare-articles/New-Drugs-for-Diabetes-Treatment-509/2 4 8/10/17 Glucagon-like peptide-1 receptor agonists Approved GLP-1 agonists: • Albiglutide (Tanzeum)* • Dulaglutide (Trulicity)* (Once-weekly) • exenatide (Byetta/Bydureon), approved in 2005/2012. • Exenatide (Byetta, Bydureon)* (Bydueon once weekly) • Liraglutide (Victoza)* • liraglutide (Victoza, Saxenda), approved 2010. • A1C reduction: 0.8% to 2.0% • lixisenatide (Lyxumia), approved in 2016. • SE: Nausea, vomiting, sense of fullness • albiglutide (Tanzeum), approved in 2014 by GSK. • Weight loss of 1 to 4 kg (2.2 to 8.8 lb) is likely • Precautions: Pancreatitis (rare) • dulaglutide (Trulicity), approved in 2014—manufactured by Eli Lilly. • Exenatide is not recommended if creatinine clearance < 30 mL per minute per 1.73 m2 (0.50 mL per second per m2) • Boxed warning for personal or family history of medullary thyroid carcinoma; patients with multiple endocrine neoplasia type 2 American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37(suppl 1):S14-S80. Glucagon-like peptide-1 receptor agonist - Wikipedia Powers AC, D'Alessio D. Chapter 43. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman's Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill; 2011 https://en.wikipedia.org/wiki/Glucagon-like_peptide-1_receptor_ agonist GLP1 Meglitinides • Exenatide is injected under the skin twice a day or once-weekly (Bydureon) within 60 minutes prior to meals. • Close potassium channels in β-cells; • Liraglutide is injected under the skin once daily at any time of the day. • Stimulate release of insulin from the pancreas • When GLP-1 receptor agonists are used in combination with a sulfonylurea, the risk of hypoglycemia increases. • Medication starts to work after 1st dose • Clinical trial data for GLP-1 receptor agonists have shown a weight loss of 2.3 to 2.8 kg when used as monotherapy and a range of 2.6 to 2.9 kg when used in combination with metformin. • Clinical results have demonstrated liraglutide’s potential as a weight loss drug for non- diabetic, obese patients. • After 1 year, liraglutide subjects lost 5.8 kg compared to 3.8 kg in the placebo group. The liraglutide group maintained
Load more

Recommended publications
  • Fixed Dose Combination of Voglibose & Repaglinide in the Management
    Clinical Group Global Journal of Obesity, Diabetes and Metabolic Syndrome ISSN: 2455-8583 DOI CC By Arif Faruqui* Research Article Medical Services Department, Medley Pharmaceuticals Limited, Mumbai, India Fixed Dose Combination of Voglibose Dates: Received: 09 August, 2017; Accepted: 26 August, 2017; Published: 28 August, 2017 & Repaglinide in the Management of *Corresponding author: Arif Faruqui, Medical Services Department, Medley Pharmaceuticals Limited, Mumbai, Postprandial Hyperglycemia in Indian India, E-mail: Subjects Keywords: T2DM; Postprandial hyperglycemia; Voglibose; Repaglinide https://www.peertechz.com Abstract To evaluate the effi cacy and tolerability of fi xed dose combination of voglibose and repaglinide in postprandial hyperglycemia (PPHG) in Indian subjects. A non-randomized, open labeled, non-comparative, single-centric, study was conducted in total of 20 type 2 diabetes mellitus (T2DM) patients (9 men and 11 women, mean age 69.07 ± 3.495 years). Each patient was administered a fi xed dose combination of voglibose 0.3mg and repaglinide 0.5/1mg three times a day, just before each meal for 30 days. Fasting blood glucose (FBG) and postprandial blood glucose (PPBG) was performed at baseline and at the end of study as assessment tools. At the end of study data was extractable only in 15 patients because 5 patient dropped out as they did not turn up for follow up at day 30.Postprandial blood glucose reduced signifi cantly {-61.67mg/dl (95% confi dence interval -76.79 to -46.54 p<0.0001)} from baseline at day 30. Also a signifi cant reduction (p<0.0001) was found with FBG {-42.13mg/dl (Confi dence interval -61.25 to -23.02 P value <0.0001)} at end of day 30.
    [Show full text]
  • Treatment of Diabetes Mellitus
    TREATMENT OF DIABETES MELLITUS DIABETES is a condition that affects how the body makes energy from food. Food is broken down into sugar (glucose) in the body and released into the blood. When the blood sugar level rises after a meal, insulin responds to let the sugar into the cells to be used as energy. In diabetes, the body either does not make enough insulin or it stops responding to insulin as well as it should. This results in sugar staying in the blood and leads to serious health problems over time. DIAGNOSIS OF DIABETES1 • A1C Test: Lab test measuring average blood sugar over past two to three months • Fasting Blood Sugar Test: Lab test measuring blood sugar after eight hours of no food or drink • Oral Glucose Tolerance Test (OGTT): Measures blood sugar before and two hours after drinking a specific sugary liquid • Random Blood Sugar Test: Measures blood sugar at a moment in time, without any kind of preparation (like fasting) FASTING BLOOD ORAL GLUCOSE TOLERANCE RANDOM BLOOD RESULT A1C TEST SUGAR TEST TEST SUGAR TEST Diabetes ≥ 6.5% ≥126 mg/dL ≥ 200 mg/dL ≥ 200 mg/dL Prediabetes 5.7 – 6.4% 100 – 125 mg/dL 140 – 199 mg/dL N/A Normal < 5.7% ≤99 mg/dL < 140 mg/dL N/A NON-DRUG TREATMENTS2 THERAPY COST WHAT TO EXPECT Diet (Mediterranean diet) and exercise (30 minutes a day, five days a week of moderate- Weight loss $-$$ intensity exercise); 7% weight loss decreases risk of diabetes3 Psychological intervention $$-$$$ Psychotherapy may reduce diabetic distress and improve glycemic control4,5 nationalcooperativerx.com PRESCRIPTION TREATMENTS
    [Show full text]
  • 295-304 Research Article Pulsatile Drug Delivery of Chitosan Co
    Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2015, 7(12):295-304 ISSN : 0975-7384 Research Article CODEN(USA) : JCPRC5 Pulsatile drug delivery of chitosan coated beads of miglitol with fast dissolving glimepiride tablet Bhise S. H.*, Surve B. S., Aloorkar N. H., Majumdar S. H. and Kulkarni A. S. Department of Pharmaceutics, Satara College of Pharmacy, Satara, Shivaji University, Maharashtra, India _____________________________________________________________________________________________ ABSTRACT : Pulsatile drug delivery system was developed which have three parts fast dissolving tablet of glimepiride, sustained release chitosan coated microbeads of miglitol and plug of HPMC E5 and spray dried lactose. After pre- formulation studies fast dissolving tablets were prepared by direct compression method; which shows instant drug release and % CDR of glimepiride fast dissolving tablet was found to be 70.81%. polymer plug have lag time 2.30 hr, chitosan coated miglitol beads shows sustained release upto 81.66% .this system is evaluated using different physicochemical parameters and in-vitro studies. Result suggests that the system can be applicable for diabetes treatment. Key words: Pulsatile, microbeads, sustained release, miglitol, glimepiride. _____________________________________________________________________________________________ INTRODUCTION Oral controlled drug delivery systems represent the most popular form of controlled drug delivery system which release the drug with constant or variable release rates.[1] Dose of drug, reduced dosage frequency, avoidance of side effects, and improved patient compliance. However, there are certain conditions for which such a release pattern is not suitable. These conditions demand release of drug after a lag time. In other words, it is required that the drug should not be released at all during the initial phase of dosage form administration.
    [Show full text]
  • Effect of the Α-Glucosidase Inhibitor Miglitol on the Glucose Profile in Japanese Type 2 Diabetic Patients Receiving Multiple Daily Insulin Injections
    Endocrine Journal 2012, 59 (4), 345-352 ORIGINAL Effect of the α-glucosidase inhibitor miglitol on the glucose profile in Japanese type 2 diabetic patients receiving multiple daily insulin injections Hiroyuki Kato, Akio Ohta, Suzuko Kobayashi, Satoshi Ishii, Yukiyoshi Sada, Hidetoshi Kobayashi, Shintaro Ohmori, Akihiko Kondo, Takuyuki Katabami, Junro Fuse, Hisashi Fukuda, Yoshio Nagai and Yasushi Tanaka Department of Internal Medicine, Division of Metabolism and Endocrinology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan Abstract. Strict postprandial glycemic control may have a preventive effect on atherogenesis in patients with type 2 diabetes. The α-glucosidase inhibitor (α-GI) miglitol is useful for controlling the early postprandial increase of glucose, but the combined effect of miglitol and multiple daily insulin injections (MDI) on glucose excursion has not been evaluated. First, we retrospectively compared the daily glucose profile, evaluated by self-monitoring of blood glucose (SMBG) at nine times on the day before discharge from hospital, between type 2 diabetic patients receiving MDI (n=81) or MDI plus miglitol at 150 mg daily (n=24). Second, we prospectively examined the effect of adding miglitol to MDI on the daily glucose profile (SMBG) in 19 other type 2 diabetic patients. Although the daily insulin dosage and the glucose level before meals did not differ between the two groups, the 1-h postprandial glucose level after each meal, 2-h glucose level after lunch and dinner, mean and standard deviation of glucose, and amplitude of glucose excursion were significantly lower or smaller in the MDI plus miglitol group than in the MDI group.
    [Show full text]
  • Hypoglycemia in Diabetes: Common, Often Unrecognized
    REVIEW ILAN GABRIELY, MD HARRY SHAMOON, MD CME Diabetes Research Center, Albert Einstein Professor of Medicine, Diabetes Research CREDIT College of Medicine, New York Center, Albert Einstein College of Medicine, New York Hypoglycemia in diabetes: Common, often unrecognized ■ ABSTRACT YPOGLYCEMIA poses a major barrier to H diabetes treatment. On one hand, we Hypoglycemic episodes in patients with diabetes often go want to maintain tight glycemic control to unrecognized, and over time, patients may lose the ability prevent the vascular complications of diabetes, to sense hypoglycemia, increasing their risk. Intensive but we also have to ensure the safety and com- diabetes control is beneficial for patients with diabetes, fort of the patient by avoiding hypoglycemia— but it increases their risk of hypoglycemia, underscoring and by recognizing and treating it if it occurs. the complexity of diabetes management. Hypoglycemic events are probably com- mon, especially in patients with type 1 diabetes. ■ KEY POINTS And when patients with type 2 diabetes receive insulin, they may become more prone to hypo- Epinephrine release during hypoglycemia becomes glycemic episodes. Unfortunately, the more progressively defective in type 1 diabetes. This decrease in episodes of hypoglycemia a patient has, the epinephrine response is accompanied by an attenuated more the body’s response is blunted, decreasing autonomic neural response, which results in the clinical the patient’s awareness of an episode. syndrome of impaired awareness of hypoglycemia (ie, Thus, we need to be vigilant in monitor- lack of the warning symptoms of prevailing ing patients for increasing episodes of hypo- glycemia, and for events that a patient may not hypoglycemia).
    [Show full text]
  • Women with Higher BMI at Lower Risk for Glaucoma
    44 WOMEN'S HEALTH SEPTEMBER 1, 2010 • FAMILY PRACTICE NEWS DRUGS, PREGNANCY, AND LACTATION Use of Antidiabetic Agents During Pregnancy n a previous column, I looked at the abinese), tolazamide (Tolinase), and tolbu- thetic analogue of human amylin given was discovered. No developmental toxi- ways uncontrolled hyperglycemia tamide (Orinase). They can cause marked by subcutaneous injection, but the ani- city was observed in the newborns. Iduring pregnancy causes significant and persistent neonatal hypoglycemia if mal data suggest moderate risk (struc- Pioglitazone (Actos) and rosiglitazone toxicity for the mother, embryo, fetus, taken close to birth. To prevent this toxi- tural anomalies in rats). The drug— (Avandia), thiazolidinediones used as ad- newborn, and adolescent (“Toxicity of city, therapy should be changed to insulin which slows the rate of gastric emptying, juncts to diet and exercise, lower insulin Diabetes in Pregnancy,” December in the third trimester or, at least, several prevents a postprandial rise in plasma resistance but do not promote insulin re- 2009, p. 52). days before birth. glucagon, and promotes satiety—is best lease. Animal reproduction data suggest This column examines the The second-generation sul- avoided in pregnancy. risk, but the human experience is too use of antidiabetic agents, fonylureas glipizide (Glu- Saxagliptin (Onglyza) and sitagliptin limited to assess the risk, so they should other than insulin, that are cotrol), glimepiride (Amaryl), (Januvia), inhibitors of the enzyme be avoided in pregnancy. used for non–insulin-depen- and glyburide (DiaBeta, Gly- dipeptidyl peptidase–4, are indicated as In summary, only metformin and gly- dent diabetes during preg- nase, and Micronase) are pre- monotherapy or in combination with buride have sufficient human pregnancy nancy and lactation.
    [Show full text]
  • The Sodium Glucose Cotransporter Type 2 Inhibitor Empagliflozin Preserves B-Cell Mass and Restores Glucose Homeostasis in the Male Zucker Diabetic Fatty Rat
    1521-0103/350/3/657–664$25.00 http://dx.doi.org/10.1124/jpet.114.213454 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 350:657–664, September 2014 Copyright ª 2014 by The American Society for Pharmacology and Experimental Therapeutics The Sodium Glucose Cotransporter Type 2 Inhibitor Empagliflozin Preserves b-Cell Mass and Restores Glucose Homeostasis in the Male Zucker Diabetic Fatty Rat Henrik H. Hansen, Jacob Jelsing, Carl Frederik Hansen, Gitte Hansen, Niels Vrang, Michael Mark, Thomas Klein, and Eric Mayoux Gubra, Hørsholm, Denmark (H.H.H., J.J., C.F.H., G.H., N.V.); and Boehringer Ingelheim Pharma, Biberach, Germany (M.M., T.K., E.M.) Received January 22, 2014; accepted July 2, 2014 Downloaded from ABSTRACT Type 2 diabetes is characterized by impaired b-cell function at week 8 of treatment compared with week 4, those of empagliflozin associated with progressive reduction of insulin secretion and remained stable throughout the study period. Similarly, empagliflozin b -cell mass. Evidently, there is an unmet need for treatments improved glucose tolerance and preserved insulin secretion jpet.aspetjournals.org with greater sustainability in b-cell protection and antidiabetic after both 4 and 8 weeks of treatment. These effects were efficacy. Through an insulin and b cell–independent mechanism, reflected by less reduction in b-cell mass with empagliflozin or empagliflozin, a specific sodium glucose cotransporter type 2 liraglutide at week 4, whereas only empagliflozin showed b-cell (SGLT-2) inhibitor, may potentially provide longer efficacy. This sparing effects also at week 8. Although this study cannot be study compared the antidiabetic durability of empagliflozin treat- used to dissociate the absolute antidiabetic efficacy among ment (10 mg/kg p.o.) against glibenclamide (3 mg/kg p.o.) and the different mechanisms of drug action, the study demon- liraglutide (0.2 mg/kg s.c.) on deficient glucose homeostasis and strates that empagliflozin exerts a more sustained improve- b-cell function in Zucker diabetic fatty (ZDF) rats.
    [Show full text]
  • Comparative Review of Oral Hypoglycemic Agents in Adults
    SECTION 18.5 Comparative Review of Oral Hypoglycemic Agents in Adults Harinder Chahal For WHO Secretariat Table of Contents Acronyms: ............................................................................................................................................................................... 3 I. Background and Rationale for the review: ....................................................................................................................... 4 II. Medications under comparative review: ......................................................................................................................... 4 Table 1 - New oral hypoglycemic agents for comparison with current EML agents .......................................................... 5 III. Literature searches and methodology: ............................................................................................................................ 5 1. Title Search Results: .................................................................................................................................................... 6 2. Statement about quality of evidence: ........................................................................................................................ 6 IV. Clinical efficacy and safety evaluation: ............................................................................................................................ 6 1. DPP-4 Inhibitors (Sitagliptin, Saxagliptin) and Metformin: ........................................................................................
    [Show full text]
  • Oral Health Fact Sheet for Dental Professionals Adults with Type 2 Diabetes
    Oral Health Fact Sheet for Dental Professionals Adults with Type 2 Diabetes Type 2 Diabetes ranges from predominantly insulin resistant with relative insulin deficiency to predominantly an insulin secretory defect with insulin resistance, American Diabetes Association, 2010. (ICD 9 code 250.0) Prevalence • 23.6 million Americans have diabetes – 7.8% of U.S. population. Of these, 5.7 million do not know they have the disease. • 1.6 million people ≥20 years of age are diagnosed with diabetes annually. • 90–95% of diabetic patients have Type 2 Diabetes. Manifestations Clinical of untreated diabetes • High blood glucose level • Excessive thirst • Frequent urination • Weight loss • Fatigue Oral • Increased risk of dental caries due to salivary hypofunction • Accelerated tooth eruption with increasing age • Gingivitis with high risk of periodontal disease (poor control increases risk) • Salivary gland dysfunction leading to xerostomia • Impaired or delayed wound healing • Taste dysfunction • Oral candidiasis • Higher incidence of lichen planus Other Potential Disorders/Concerns • Ketoacidosis, kidney failure, gastroparesis, diabetic neuropathy and retinopathy • Poor circulation, increased occurrence of infections, and coronary heart disease Management Medication The list of medications below are intended to serve only as a guide to facilitate the dental professional’s understanding of medications that can be used for Type 2 Diabetes. Medical protocols can vary for individuals with Type 2 Diabetes from few to multiple medications. ACTION TYPE BRAND NAME/GENERIC SIDE EFFECTS Enhance insulin Sulfonylureas Glipizide (Glucotrol) Angioedema secretion Glyburide (DiaBeta, Fluconazoles may increase the Glynase, Micronase) hypoglycemic effect of glipizide Glimepiride (Amaryl) and glyburide. Tolazamide (Tolinase, Corticosteroids may produce Diabinese, Orinase) hyperglycemia. Floxin and other fluoroquinolones may increase the hypoglycemic effect of sulfonylureas.
    [Show full text]
  • Impact of Voglibose on the Pharmacokinetics of Dapagliflozin
    Diabetes Ther (2013) 4:41–49 DOI 10.1007/s13300-012-0016-5 ORIGINAL RESEARCH Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes Akira Imamura • Masahito Kusunoki • Shinya Ueda • Nobuya Hayashi • Yasuhiko Imai To view enhanced content go to www.diabetestherapy-open.com Received: September 24, 2012 / Published online: January 10, 2013 Ó The Author(s) 2013. This article is published with open access at Springerlink.com ABSTRACT glucose reabsorption. This study was performed to assess the effect of the oral antidiabetic agent Introduction: Dapagliflozin is an orally voglibose [0.2 mg thrice daily (t.i.d.)] at steady- administered selective sodium-glucose state, on the pharmacokinetics, safety and cotransporter 2 (SGLT2) inhibitor under tolerability of dapagliflozin administered as a development for the treatment of type 2 single oral dose (10 mg) to Japanese patients diabetes mellitus (T2DM). Dapagliflozin lowers with T2DM. blood glucose through a reduction in renal Methods: This was an open-label, multi-center, ClinicalTrials.gov: #NCT01055652. drug–drug interaction study. A single oral dose of dapagliflozin (10 mg) was administered to 22 A. Imamura (&) Japanese patients with T2DM in the presence Moriya Keiyu Hospital, 980-1, Tatuzawa, and absence of voglibose (0.2 mg t.i.d.). Serial Moriya City, Ibaraki 302-0118, Japan e-mail: [email protected] blood samples were collected before and at regular prespecified intervals after each M. Kusunoki The Institute for Rehabilitation Studies, Kobe dapagliflozin dose to determine dapagliflozin International University, 9-1-6 Koyocho-naka, plasma concentrations and to evaluate Higashinada-ku, Kobe-city, Hyogo 658-0032, Japan pharmacokinetic parameters.
    [Show full text]
  • Diabetes Recommendations and Tier Coverage Chart
    DIABETES RECOMMENDATIONS AND TIER COVERAGE CHART The American Diabetes Association guidelines for 2020, recommend metformin as the preferred initial treatment for type 2 diabetes (T2DM) along with weight management and physical activity. In patients who have established ASVD or at high risk, CKD, or HF, a SGLT2i or GLP-1 receptor with proven efficacy is recommended independent of A1C. • ASCVD dominates: o GLP-1RA with proven CVD benefit (dulaglutide, liraglutide, injectable semaglutide) OR o SGLT2i with proven CVD benefit (canagliflozin, empagliflozin) if adequate eGFR • HF or CKD dominates: o SGLT2i with evidence of reducing HF and/or CKD progression (empagliflozin, canagliflozin, dapagliflozin) if adequate eGFR OR o If SGLT2i intolerant/contraindicated or eGFR is inadequate, then GLP-1RA with proven CVD benefit In individuals without established cardiovascular disease, pharmacological treatment should be patient-centered taking into account side-effects, cost, impact on weight, risk of hypoglycemia, and other patient preferences. For more detailed information regarding ADA recommendations for pharmacological agents to treat T2DM click here. The following chart is a list of oral and injectable diabetes medications listed by class with their respective A1C reduction and insurance coverage and/or coverage requirements for BCBS, HPHC, Tufts, TMP, and MassHealth. Tufts Medicare Medications BCBSMA HPHC Tufts Preferred MassHealth Biguanides A1C reduction: 1-1.5% metformin Tier 1 Tier 1;2 Tier 1 Tier 1 Covered Glucoghage (metformin) NC NC NC;Tier
    [Show full text]
  • The Synergistic Effect of Miglitol Plus Metformin Combination Therapy in the Treatment of Type 2 Diabetes
    Clinical Care/Education/Nutrition ORIGINAL ARTICLE The Synergistic Effect of Miglitol Plus Metformin Combination Therapy in the Treatment of Type 2 Diabetes 1 JEAN-LOUIS CHIASSON, MD The recently developed class of 2 LISA NADITCH, MD ␣-glucosidase inhibitors has a unique FOR THE MIGLITOL CANADIAN UNIVERSITY mode of action; it blocks oligosaccharide INVESTIGATOR GROUP catabolism, delays carbohydrate diges- tion and absorption, and smooths and lowers postprandial plasma blood glu- cose peaks (6–9). Substantial evidence supports their use as monotherapy or ad- OBJECTIVE — To investigate the efficacy and safety of miglitol in combination with met- junct therapy for poorly controlled type 2 formin in improving glycemic control in outpatients in whom type 2 diabetes is insufficiently diabetes (5,10–14). Miglitol is the first controlled by diet alone. pseudomonosaccharide ␣-glucosidase in- RESEARCH DESIGN AND METHODS — In this multicenter, double-blind, placebo- hibitor derived from 1-deoxynojirimycin controlled study, 324 patients with type 2 diabetes were randomized, after an 8-week placebo and is structurally a glucose analog run-in period, to treatment with either placebo, miglitol alone, metformin alone, or miglitol plus (15,16). Its efficacy in monotherapy metformin for 36 weeks. The miglitol was titrated to 100 mg three times a day and metformin was (13,17) and in combination with sulfo- administered at 500 mg three times a day. The primary efficacy criterion was change in HbA1c nylureas (11) as a glucose-lowering agent from baseline to the end of treatment. Secondary parameters included changes in fasting and in type 2 diabetes has been shown in a postprandial plasma glucose and insulin levels, serum triglyceride levels, and responder rate.
    [Show full text]